{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T07:05:41Z","timestamp":1779606341641,"version":"3.53.1"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The European Union Summary of Product Characteristics (EU SmPC) for alemtuzumab in multiple sclerosis (MS) was revised in January 2020 under an Article 20 EU-pharmacovigilance procedure to include a revised indication, additional contraindications, and new monitoring requirements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate adherence to the revised SmPC for alemtuzumab across four European countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Descriptive cohort study using secondary healthcare data recorded between January 2020 (date of alemtuzumab EU SmPC revision) and the latest database update in each data source (ranging from March 2022 to January 2024).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data are used from: the Czech Republic MS registry (ReMuS), a cohort study of patients treated with alemtuzumab in Germany (long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing-remitting MS (TREAT-MS)), chart review data from three United Kingdom (UK) centers, and administrative healthcare data from the Belgian Social Security database (L\u2019Agence InterMutualiste\u2014Het InterMutualistisch Agentschap (AIM-IMA)). Adherence to revised indications, contraindications, and safety monitoring was summarized descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Data from 2046 people with MS treated with at least one course of alemtuzumab were assessed. Of 155 patients evaluable for adherence to the indication, 66.7% met the revised indication in ReMuS (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 54\/81; increasing to 75.3% after manual checks), 87.5% in TREAT-MS (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 7\/8), 66.7% in UK centers (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 26\/39; increasing to 79.5% in sensitivity analyses), and 100.0% in AIM-IMA (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 22). Of 549 courses evaluated, 77.5%\u201397.8% were not contraindicated. While adherence to safety monitoring tests varied, heart rate and blood pressure were recorded for \u2a7e77.5% of courses before treatment and \u2a7e83.1% of courses during treatment. Platelet testing was conducted for 29.1%\u201351.4% of courses during treatment. Adherence to long-term (up to month 48) post-infusion monitoring was approximately 50%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Alemtuzumab was prescribed in accordance with the indication in 67%\u201388% of patients included in this study. It was prescribed in accordance with the listed contraindications in 78%\u201398% of courses included in the study. Adherence to the monitoring schedule is adequate to maintain the benefit\u2013risk profile of alemtuzumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic toggle=\"yes\">Trial registration:<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>\n                      This study was registered in the Heads of Medicines Agency European Medicines Agency (EMA) catalog (EUPAS42540). Results are available on the EMA website:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/catalogues.ema.europa.eu\/node\/3602\/resources\">https:\/\/catalogues.ema.europa.eu\/node\/3602\/resources<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864261444676","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:25:26Z","timestamp":1779423926000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-4456","authenticated-orcid":false,"given":"Carmen","family":"de Keijzer","sequence":"first","affiliation":[{"name":"Epidemiology and Real-World Research, and Biostatistics, Parexel International, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6175-6974","authenticated-orcid":false,"given":"Jian-Yu","family":"E","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[{"name":"Epidemiology and Real-World Research, and Biostatistics, Parexel International, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gitonga","sequence":"additional","affiliation":[{"name":"Epidemiology and Real-World Research, and Biostatistics, Parexel International, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hiller","sequence":"additional","affiliation":[{"name":"Epidemiology and Real-World Research, and Biostatistics, Parexel International, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Jurgensen","sequence":"additional","affiliation":[{"name":"Clinical Development, Sanofi, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naji","family":"Salloum","sequence":"additional","affiliation":[{"name":"Sanofi, Gentilly, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janete","family":"Cunha-Santos","sequence":"additional","affiliation":[{"name":"Sanofi Produtos Farmac\u00eauticos Lda, Porto Salvo, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Hoogewys-Cynober","sequence":"additional","affiliation":[{"name":"Sanofi, Gentilly, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Vinet","sequence":"additional","affiliation":[{"name":"Cytel: Functional Service Provider, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Chirieac","sequence":"additional","affiliation":[{"name":"Patient Safety and Pharmacovigilance, Sanofi, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadj","family":"Benzerdjeb","sequence":"additional","affiliation":[{"name":"Sanofi, Gentilly, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Thoene","sequence":"additional","affiliation":[{"name":"Sanofi, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8799-8202","authenticated-orcid":false,"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[{"name":"Center of Clinical Neuroscience, Department of Neurology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3416-2094","authenticated-orcid":false,"given":"Ji\u0159\u00ed","family":"Drahota","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic"},{"name":"ReMuS\u2014The Czech Multiple Sclerosis Patient Registry, ReMuS Endowment Fund, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-0036","authenticated-orcid":false,"given":"Dana","family":"Hor\u00e1kov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic"},{"name":"ReMuS\u2014The Czech Multiple Sclerosis Patient Registry, ReMuS Endowment Fund, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7737-5834","authenticated-orcid":false,"given":"William","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-7920","authenticated-orcid":false,"given":"Jeremy","family":"Hobart","sequence":"additional","affiliation":[{"name":"Plymouth University Peninsula Medical School, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Robertson","sequence":"additional","affiliation":[{"name":"Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja M.","family":"Hakkarainen","sequence":"additional","affiliation":[{"name":"Epidemiology and Real-World Research, and Biostatistics, Parexel International, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7586-686X","authenticated-orcid":false,"given":"Sarah-Jo","family":"Sinnott","sequence":"additional","affiliation":[{"name":"Epidemiology and Benefit\u2013Risk Evaluation, Sanofi, 450 Water St., Cambridge, MA 02141, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802670"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420982134"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.P3.2-058"},{"key":"e_1_3_5_7_2","unstructured":"European Medicines Agency. Lemtrada article 20 procedure\u2014measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_en.pdf-0 (2020 accessed 28 January 2025)."},{"key":"e_1_3_5_8_2","unstructured":"European Medicines Agency. Lemtrada summary of product characteristics https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lemtrada#product-information-section (2024 accessed 27 August 2025)."},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0629-9"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.620758"},{"key":"e_1_3_5_11_2","author":"European Medicines Agency","unstructured":"European Medicines Agency. Lemtrada: international non-proprietary name: ALEMTUZUMAB. Committee for Medicinal Products for Human Use, Report no. EMEA\/H\/C\/003718\/0000, 2013.","journal-title":"Lemtrada: international non-proprietary name: ALEMTUZUMAB"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.039"},{"key":"e_1_3_5_13_2","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan SM","year":"2018","unstructured":"Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018; 363: k3532.","journal-title":"BMJ"},{"key":"e_1_3_5_14_2","unstructured":"S\u00daKL P\u0159ehled l\u00e9\u010div. Detail varianty l\u00e9\u010div\u00e9ho p\u0159\u00edpravku LEMTRADA (0194394-12MG INF CNC SOL 1X1 2ML)."},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.1522"},{"key":"e_1_3_5_16_2","unstructured":"NHS UK. Treatment algorithm multiple sclerosis disease-modifying therapies [internet]. MS algorithm V5 https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2018\/09\/ms-algorithm-v5.pdf (2018 accessed 16 January 2025)."},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4146"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-1030"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1361-2"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13247757"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520910500"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.17712\/nsj.2024.3.20240040"},{"key":"e_1_3_5_23_2","article-title":"Implementation of a safety program initiative for monitoring infusion disease modifying therapies for multiple sclerosis","volume":"11","author":"Roy S","year":"2025","unstructured":"Roy S, Haughton J, Vaidya D, et al. Implementation of a safety program initiative for monitoring infusion disease modifying therapies for multiple sclerosis. Mult Scler J Exp Transl Clin 2025; 11: 20552173251320791.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211005339"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102512"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00217-5"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211030656"},{"key":"e_1_3_5_28_2","unstructured":"Association of British Neurologists MS and Neuroinflammation Advisory Group. ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the COVID19 pandemic https:\/\/cdn.ymaws.com\/www.theabn.org\/resource\/collection\/6750BAE6-4CBC-4DDB-A684-116E03BFE634\/21.10.26_ABN_Guidance_on_DMTs_for_MS_and_COVID-19.pdf (2021 accessed 27 August 2025)."},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577627"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-13-128"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.04.004"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1437144"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261444676","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864261444676","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261444676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T06:16:59Z","timestamp":1779603419000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864261444676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"alternative-id":["10.1177\/17562864261444676"],"URL":"https:\/\/doi.org\/10.1177\/17562864261444676","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"17562864261444676"}}